Rui Zheng Gene

Ruizheng Gene is a biotechnology company headquartered in Suzhou, China, focused on developing innovative in vivo gene editing therapies. The company utilizes advanced CRISPR-based technologies and proprietary lipid nanoparticle (LNP) delivery systems to target chronic and genetic diseases, particularly those affecting the liver. Its lead programs aim to provide one-time curative treatments for cardiovascular and metabolic conditions such as hypercholesterolemia. Ruizheng Gene was founded by industry veterans with extensive experience in global gene editing firms, positioning it as a key player in the Chinese genomic medicine landscape. The company's platform emphasizes high-efficiency editing and precise delivery to minimize off-target effects. With significant backing from prominent venture capital firms, Ruizheng is advancing its pipeline toward clinical-stage development.